Circulating Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 (sLOX-1): A Diagnostic Indicator across the Spectrum of Acute Coronary Syndrome

Kumar, Sandeep; Ali, Wahid; Mishra, Sridhar; Pradhan, Akshyaya; Sethi, Rishi; Kushwaha, Rashmi; Singh, U. S.; Perrone, Marco Alfonso

doi:10.3390/jcm10235567

Cited by 9 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is known that patients with dyslipidemia and systemic inflammation have a significant increase in CVD events. 5 , 7 , 22 Inflammation and metabolic dysfunction drive posttranslational modifications of low‐density lipoprotein, such as low‐density lipoprotein oxidation by reactive oxygen species. 23 Once oxLDL is internalized in the arterial wall by endothelial cells and macrophages, LOX‐1 has been shown to facilitate neointima formation and proliferation.…”

Section: Discussionmentioning

confidence: 99%

Relationship of Soluble Lectin‐Like Low‐Density Lipoprotein Receptor‐1 (sLOX‐1) With Inflammation and Coronary Plaque Progression in Psoriasis

Florida,

Li,

Hong

et al. 2023

JAHA

View full text Add to dashboard Cite

Background Psoriasis is a chronic inflammatory condition associated with coronary artery disease risk. Uptake of oxidized low‐density lipoprotein by the lectin‐like low‐density lipoprotein receptor‐1 triggers release of the soluble extracellular domain of the receptor (sLOX‐1). We sought to characterize the relationship between sLOX‐1, inflammation, and coronary plaque progression in psoriasis. Methods and Results A total of 327 patients with psoriasis had serum sLOX‐1 levels measured at baseline by an ELISA‐based assay. Stratification by high‐sensitivity C‐reactive protein ≥4.0 mg/L (quartile 4), identified 81 participants who had coronary plaque phenotyping at baseline and were followed longitudinally by coronary computed tomography angiography. Subjects within high‐sensitivity C‐reactive protein quartile 4 were middle‐aged (51.47±12.62 years), predominantly men (54.3%) with moderate psoriasis disease severity (6.60 [interquartile range, 3.30–13.40]). In the study cohort, participants with sLOX‐1 above the median displayed increased vulnerable coronary plaque features. At baseline, sLOX‐1 was associated with total burden (rho=0.296; P =0.01), noncalcified burden (rho=0.286; P =0.02), fibro‐fatty burden (rho=0.346; P =0.004), and necrotic burden (rho=0.394; P =0.002). A strong relationship between sLOX‐1, noncalcified burden ( β =0.19; P =0.03), and fibro‐fatty burden ( β =0.29; P =0.003) was found in fully adjusted models at baseline and 1‐ and 4‐year follow‐up. Finally, coronary plaque features progressed over 1 year regardless of biologic or systemic treatment in subjects with high sLOX‐1. Conclusions Patients with psoriasis with both high sLOX‐1 and high‐sensitivity C‐reactive protein levels have increased coronary plaque burden associated with atherosclerotic plaque progression independent of biologic and systemic treatment. Thus, sLOX‐1 might be considered as a promising marker in coronary artery disease risk estimation beyond traditional risk factors. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01778569.

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship of Soluble Lectin‐Like Low‐Density Lipoprotein Receptor‐1 (sLOX‐1) With Inflammation and Coronary Plaque Progression in Psoriasis

Florida,

Li,

Hong

et al. 2023

JAHA

View full text Add to dashboard Cite

show abstract

“…The sLOX-1 is a therapeutic target for atherosclerotic diseases [21] and acute cerebral infarction [22,23]. It is associated with cardiovascular and cerebrovascular events in patients undergoing percutaneous coronary surgery [24,25] and is even related to inflammatory diseases such as sleep apnea [26]; moreover, in patients with rheumatoid arthritis (the soluble portion of LOX-1 has been identified in synovial fluid) [27] and obesity [28].…”

Section: Polymorphisms Mutations and Isotypes Of Lox-1mentioning

confidence: 99%

LOX-1 in Cardiovascular Disease: A Comprehensive Molecular and Clinical Review

Sánchez-León,

Loaeza-Reyes,

Matias-Cervantes

et al. 2024

IJMS

View full text Add to dashboard Cite

LOX-1, ORL-1, or lectin-like oxidized low-density lipoprotein receptor 1 is a transmembrane glycoprotein that binds and internalizes ox-LDL in foam cells. LOX-1 is the main receptor for oxidized low-density lipoproteins (ox-LDL). The LDL comes from food intake and circulates through the bloodstream. LOX-1 belongs to scavenger receptors (SR), which are associated with various cardiovascular diseases. The most important and severe of these is the formation of atherosclerotic plaques in the intimal layer of the endothelium. These plaques can evolve into complicated thrombi with the participation of fibroblasts, activated platelets, apoptotic muscle cells, and macrophages transformed into foam cells. This process causes changes in vascular endothelial homeostasis, leading to partial or total obstruction in the lumen of blood vessels. This obstruction can result in oxygen deprivation to the heart. Recently, LOX-1 has been involved in other pathologies, such as obesity and diabetes mellitus. However, the development of atherosclerosis has been the most relevant due to its relationship with cerebrovascular accidents and heart attacks. In this review, we will summarize findings related to the physiologic and pathophysiological processes of LOX-1 to support the detection, diagnosis, and prevention of those diseases.

show abstract

“…Integration of ischemic risk and bleeding risk of the patient in decisions regarding initiation and extension of dual antiplatelet therapy is advocated by guidelines. The ESC 2017 update on antiplatelets strongly advocates for the use of DAPT and PRECISE DAPT score in decision making [ 83 , 84 , 85 , 86 ]. The 2018 CCS guidelines on antiplatelet therapy have indicated clinical conditions with high ischemic risk warranting novel P2Y12i like multivessel disease, multiple stents, complex bifurcation, total stent length > 60 mm, chronic total occlusion, and bioabsorbable vascular scaffold [ 59 ]…”

Section: Mitigation Of Bleedingmentioning

confidence: 99%

Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status

Pradhan

Tiwari

Caminiti

et al. 2022

IJERPH

Self Cite

View full text Add to dashboard Cite

Dual antiplatelet therapy (DAPT) has remained a cornerstone for management of acute coronary syndrome (ACS) over the years. Clopidogrel has been the quintessential P2Y12 receptor (platelet receptor for Adenosine 5′ diphosphate) inhibitor for the past two decades. With the demonstration of unequivocal superior efficacy of prasugrel/ticagrelor over clopidogrel, guidelines now recommend these agents in priority over clopidogrel in current management of ACS. Cangrelor has revived the interest in injectable antiplatelet therapy too. Albeit the increased efficacy of these newer agents comes at the cost of increased bleeding and this becomes more of a concern when combined with aspirin. Which P2Y12i is superior over another has been intensely debated over last few years after the ISAR-REACT 5 study with inconclusive data. Three novel antiplatelet agents are already in the pipeline of ACS with all of them succeeding in phase II studies. The search for an ideal antiplatelet remains a need of the hour for optimal reduction of ischemic events in ACS.

show abstract

Circulating Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 (sLOX-1): A Diagnostic Indicator across the Spectrum of Acute Coronary Syndrome

Cited by 9 publications

References 23 publications

Relationship of Soluble Lectin‐Like Low‐Density Lipoprotein Receptor‐1 (sLOX‐1) With Inflammation and Coronary Plaque Progression in Psoriasis

Relationship of Soluble Lectin‐Like Low‐Density Lipoprotein Receptor‐1 (sLOX‐1) With Inflammation and Coronary Plaque Progression in Psoriasis

LOX-1 in Cardiovascular Disease: A Comprehensive Molecular and Clinical Review

Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status

Contact Info

Product

Resources

About